The First Patient Included in Australia in Isofol's Phase 3 AGENT Study

GOTHENBURG, Sweden, Jan. 24, 2020 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Australia has initiated treatment in the global Phase 3 AGENT study....
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Friday, 24 January

Share |